Phenytoin immunoassay measurements in serum samples from patients with renal insufficiency: comparison with high‐performance liquid chromatography
Tóm tắt
The debate continues regarding the possible interference of phenytoin metabolites in phenytoin immunoassays, and its clinical importance for patients with renal failure. The aim of this study was to compare the results obtained using the Abbott fluorescence polarization immunoassay (FPIA), Dade enzyme‐multiplied immunoassay technique (EMIT), and high‐performance liquid chromatography (HPLC) to establish the significance of the differences in conditions of renal failure. Thirty‐six adult patients who had been treated with phenytoin and whose renal function ranged from normal to severely impaired were chosen for this study. In accordance with previously established validation criteria for analytical methods for the determination of drugs, a 15% bias from the HPLC phenytoin values was considered an acceptable limit. The mean (±SEM) glomerular filtration rate (GFR) of the patients was 37.5±4.6 mL/min (range = 10–102 mL/min).The mean values found using FPIA (10.8±1.2 µg/mL) and EMIT (10.8±1.3 µg/mL) presented acceptable deviations with respect to HPLC (10.5±1.2 µg/mL), and a high correlation was found among the results (
Từ khóa
Tài liệu tham khảo
Finn AL, 1981, Individualizing drug monitoring. Practical applications of drug monitoring, 63
Nakajima M, 2002, Involvement of multiple UDP‐glucuronosyltransferase 1A isoforms in glucuronidation of 5‐(4′‐hydroxyphenyl)‐5‐phenylhydantoin in human liver microsomes, Drug Metab Dispos, 27, 1165
Flachs H, 1980, Renal disease may increase apparent phenytoin in serum as measured by enzyme‐multiplied immunoassay, Clin Chem, 26, 361, 10.1093/clinchem/26.2.361
Rubenstein K, 1980, Renal disease may increase apparent phenytoin in serum as measured by enzyme‐multiplied immunoassay [reply], Clin Chem, 26, 362
Roberts WL, 1993, Interference in immunoassay measurements of total and free phenytoin in uremic patients: a reappraisal, Clin Chem, 39, 1872, 10.1093/clinchem/39.9.1872
Rainey PM, 1996, Metabolite and matrix interference in phenytoin immunoassays, Clin Chem, 42, 1645, 10.1093/clinchem/42.10.1645
Datta P, 1997, Oxaprozin and 5‐(p‐hydroxyphenyl)‐5‐phenylhydantoin interference in phenytoin immunoassays, Clin Chem, 43, 1468, 10.1093/clinchem/43.8.1468
Soldin SJ, 2003, Phenytoin overview–metabolite interference in some immunoassays could be clinically important, Arch Pathol Lab Med, 127, 1623, 10.5858/2003-127-1623-POIISI
Roberts WL, 2004, Phenytoin overview–metabolite interference in some immunoassays could be clinically important, Arch Pathol Lab Med, 128, 734, 10.5858/2004-128-734-POMIIS
Soldin SJ, 2004, Phenytoin overview–metabolite interference in some immunoassays could be clinically important, Arch Pathol Lab Med, 128, 734, 10.5858/2004-128-734-POMIIS
Eksborg S, 1981, Evaluation of method–comparison data, Clin Chem, 27, 1311, 10.1093/clinchem/27.7.1311
Perucca E, 1981, Therapeutic drug monitoring, 320